PCSK9 and cancer: The lack of reductions in cancer incidence in clinical trials on cardiovascular conditions by anti-PCSK9 antibodies evolocumab and alirocumab [45, 46] might be attributable to the presence of cancerous lesions at time when the antibodies were administrated.